Incidence of hepatic dysfunction is equivalent in burn patients receiving oxandrolone and controls

J Burn Care Res. May-Jun 2007;28(3):412-20. doi: 10.1097/BCR.0B013E318053D257.

Abstract

Oxandrolone has been shown to improve lean muscle mass in patients with burns. Hepatic dysfunction is a known side effect of treatment with oxandrolone. The purpose of this study was to examine the incidence of hepatic dysfunction in our series of burn patients receiving oxandrolone. Fourteen patients who received oxandrolone (5 mg, n = 8; 10 mg, n = 6) were identified from our prospectively collected burn database. The records of 61 control patients also were reviewed. Demographics such as age, comorbidities, and burn size were recorded. The incidence of hepatic dysfunction was determined by the presence of abnormal liver function tests. The study and control groups were similar in age and burn size. Two of the eight (25%) oxandrolone patients receiving 5 mg and four of the six (67%) oxandrolone patients receiving 10 mg had evidence of hepatic dysfunction. Twenty six of the 61 (43%) control patients had evidence of hepatic dysfunction (P = NS). There appears no significant increased incidence of hepatic dysfunction in burn patients who received oxandrolone compared to those who did not.

MeSH terms

  • Adult
  • Alanine Transaminase / drug effects
  • Anabolic Agents / adverse effects*
  • Anabolic Agents / therapeutic use
  • Androgens / adverse effects*
  • Androgens / therapeutic use
  • Aspartate Aminotransferases / drug effects
  • Body Composition / drug effects*
  • Burns / drug therapy*
  • Case-Control Studies
  • Chemical and Drug Induced Liver Injury*
  • Female
  • Humans
  • Incidence
  • Liver / drug effects*
  • Male
  • Middle Aged
  • Oxandrolone / adverse effects*
  • Oxandrolone / therapeutic use
  • Retrospective Studies

Substances

  • Anabolic Agents
  • Androgens
  • Oxandrolone
  • Aspartate Aminotransferases
  • Alanine Transaminase